Induction Immunochemotherapy Followed by Definitive Chemoradiotherapy and Consolidation Immunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Prospective Phase II Study
- 19 November 2026
- journal article
- Published by Wiley in International Journal of Cancer
Abstract
Long‐term survival after definitive concurrent chemoradiotherapy (dCCRT) remains limited in locally advanced esophageal squamous cell carcinoma (ESCC). We evaluated induction immunochemotherapy followed by dCCRT and consolidation immunotherapy in this setting. This prospective, single‐arm Phase II study enrolled 54 adults selected for definitive nonsurgical treatment. The planned regimen comprised two cycles of induction immunochemotherapy with nab‐paclitaxel, carboplatin, and a programmed cell death protein 1 (PD‐1) inhibitor, followed by dCCRT with 50.4 Gy in 28 fractions and concurrent weekly chemotherapy. The same PD‐1 inhibitor was planned as consolidation therapy for up to 1 year. The primary endpoint was the 2‐year overall survival (OS) rate. Fifty‐three patients (98.1%) completed two induction cycles, all 54 proceeded to dCCRT, and 31 (57.4%) received consolidation immunotherapy. Among all 54 enrolled patients, the 2‐year OS and progression‐free survival (PFS) rates were 84.6% (95% confidence interval [CI], 75.2%–95.0%) and 61.5% (95% CI, 49.5%–76.4%), respectively, after a median follow‐up of 28.1 months. Adverse events occurred predominantly during dCCRT and were mainly hematologic; lymphopenia and esophagitis were among the most frequent toxicities. Exploratory analyses suggested that suboptimal response after induction immunochemotherapy was associated with shorter PFS. The survival outcomes observed with this sequential approach support further evaluation of its comparative clinical benefit in randomized studies. Trial Registration: ClinicalTrials.gov (NCT05621707)Funding Information
- Wu Jieping Medical Foundation (320.6750.2022‐09‐9)
This publication has 14 references indexed in Scilit:
- Atezolizumab with or without tiragolumab in unresectable esophageal squamous-cell carcinoma following definitive concurrent chemoradiotherapy (SKYSCRAPER-07): a randomised, phase III studyAnnals of Oncology, 2026
- Consolidative Camrelizumab Following Definitive Concurrent Chemoradiation Therapy With Involved-Field Irradiation in Locally Advanced Esophageal Squamous Cell Carcinoma: A Single-Arm Phase 2 TrialInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2026
- PL03.06 EA5181: Phase 3 Trial of Concurrent and Consolidative Durvalumab vs Consolidation Durva Alone for Unresectable Stage 3 NSCLCJournal of Thoracic Oncology, 2025
- Neoadjuvant Chemoradiotherapy vs Chemoimmunotherapy for Esophageal Squamous Cell CarcinomaJAMA Surgery, 2025
- Safety and efficacy of neoadjuvant toripalimab plus chemotherapy followed by chemoradiotherapy for locally advanced esophageal squamous cell carcinoma in China (GASTO 1071): a non-randomised, two-cohort, phase 2 trialeClinicalMedicine, 2025
- Prognostic value of systemic inflammation response index in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors: a meta-analysisAnnals of Medicine, 2024
- Perioperative outcomes and survival after neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinomaThe Journal of Thoracic and Cardiovascular Surgery, 2024
- Induction sintilimab and chemotherapy followed by concurrent chemoradiotherapy for locally advanced esophageal cancer: a proof-of-concept, single-arm, multicenter, phase 2 trialeClinicalMedicine, 2024
- Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell CarcinomaNew England Journal of Medicine, 2022
- Chemoradiotherapy of Locally Advanced Esophageal CancerJAMA, 1999